Stockreport

Tonix Pharmaceuticals Plans to Initiate Prader-Willi Syndrome Phase 2 Trial of TNX-2900 (Intranasal Potentiated Oxytocin) in 2026 [Yahoo! Finance]

Tonix Pharmaceuticals Holding Corp.  (TNXP) 
Last tonix pharmaceuticals holding corp. earnings: 3/24 05:15 pm Check Earnings Report
US:NASDAQ Investor Relations: tonixpharma.com
PDF in children and adolescents (ages 8 to 17.5 years) with Prader-Willi Syndrome under a cleared IND TNX-2900 granted Orphan Drug and Rare Pediatric Disease Designations [Read more]